Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma.
APTw
CEST
MIB-1 index
PCNSL
glioblastoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Feb 2023
02 Feb 2023
Historique:
received:
07
12
2022
revised:
26
01
2023
accepted:
28
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
Distinguishing primary central nervous system lymphoma (PCNSL) from glioblastoma, isocitrate dehydrogenase (IDH)-wildtype is sometimes hard. Because the role of operation on them varies, accurate preoperative diagnosis is crucial. In this study, we evaluated whether a specific kind of chemical exchange saturation transfer imaging, i.e., amide proton transfer-weighted (APTw) imaging, was useful to distinguish PCNSL from glioblastoma, IDH-wildtype. A total of 14 PCNSL and 27 glioblastoma, IDH-wildtype cases were evaluated. There was no significant difference in the mean APTw signal values between the two groups. However, the percentile values from the 1st percentile to the 20th percentile APTw signals and the width
Identifiants
pubmed: 36765909
pii: cancers15030952
doi: 10.3390/cancers15030952
pmc: PMC9913574
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
NMR Biomed. 2022 Jun 15;:e4785
pubmed: 35704275
Diagnostics (Basel). 2022 Feb 14;12(2):
pubmed: 35204583
Int J Mol Sci. 2022 Sep 05;23(17):
pubmed: 36077581
World Neurosurg. 2020 Jul;139:e508-e516
pubmed: 32311566
Mol Imaging Biol. 2013 Feb;15(1):114-22
pubmed: 22644987
Eur Radiol. 2019 Dec;29(12):6643-6652
pubmed: 31175415
Front Oncol. 2022 Oct 03;12:884173
pubmed: 36263203
Mol Med Rep. 2011 Nov-Dec;4(6):1101-5
pubmed: 21874248
PLoS One. 2020 Aug 13;15(8):e0237358
pubmed: 32790705
Medicine (Baltimore). 2019 Mar;98(10):e14768
pubmed: 30855481
Nucl Med Commun. 2022 Mar 1;43(3):270-274
pubmed: 34864812
Sci Rep. 2020 Jul 17;10(1):11922
pubmed: 32681084
J Neurosurg. 2011 Jul;115(1):3-8
pubmed: 21417701
NMR Biomed. 2023 Jan;36(1):e4821
pubmed: 36031734
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Neurol Med Chir (Tokyo). 2016;56(4):170-9
pubmed: 26960449
J Magn Reson Imaging. 2020 Apr;51(4):1154-1161
pubmed: 31430008
Crit Rev Oncol Hematol. 2017 May;113:97-110
pubmed: 28427529
Neuro Oncol. 2014 Mar;16(3):441-8
pubmed: 24305718
Neuroradiol J. 2010 Dec;23(6):680-9
pubmed: 24148721
J Neurosurg. 2021 Jun 04;136(1):1-8
pubmed: 34087795
J Neurosurg. 2014 Nov;121(5):1115-23
pubmed: 25192475
J Neurosurg. 2021 Oct 29;:1-9
pubmed: 34715662
Eur Radiol. 2018 May;28(5):2115-2123
pubmed: 29234914
Cancer Sci. 2016 Aug;107(8):1159-64
pubmed: 27196377
Magn Reson Med Sci. 2018 Jan 10;17(1):42-49
pubmed: 28515410
Neuroradiology. 1994 May;36(4):308-10
pubmed: 8065577
Front Oncol. 2022 Aug 01;12:852076
pubmed: 35978813
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Neuro Oncol. 2018 Nov 12;20(12):1661-1671
pubmed: 29733378
Eur J Radiol. 2020 Dec;133:109353
pubmed: 33120241
Curr Med Chem. 2016;23(38):4309-4316
pubmed: 27758718
J Magn Reson Imaging. 2022 Jul 11;:
pubmed: 35816177
Magn Reson Med. 2017 Sep;78(3):1100-1109
pubmed: 28714279
Brain Tumor Pathol. 2020 Apr;37(2):33-40
pubmed: 32227259
Eur Radiol. 2016 Jan;26(1):64-71
pubmed: 25925361
World Neurosurg. 2019 Jul;127:e779-e787
pubmed: 30951915
NMR Biomed. 2022 Mar 23;:e4734
pubmed: 35322482
Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2377-2391
pubmed: 35029738
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078